Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for ...

Novo Nordisk NOVO.B 1.19% plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is still likely to ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major competitor in China.

Pharma giant Novo Nordisk announced that it is collaborating with WeightWatchers to offer Wegovy through NovoCare Pharmacy, effective July 1. Through the partnership, WeightWatchers' telehealth ...

Novo Nordisk A/S (NYSE: NVO) is one of the 10 best defensive stocks to buy in a volatile market. On July 7, the company received a significant boost in its proposed $2.34 billion investment in a ...

Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical company that was one of the earliest movers in the weight loss drug market. The shares have lost 21% year-to-date due to multiple headwinds.

Novo Nordisk, arguing that Hims & Hers is abusing compounding as a loophole to bypass its patent, terminated the sales agreement.

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.